TMCnet News
US Breast Cancer Drug Market Outlook 2022 - Research and MarketsResearch and Markets has announced the addition of the "US Breast Cancer Drug Market Outlook 2022" report to their offering. US breast cancer market is conquered by monoclonal antibodies due to superior pharmacological effects and availability of large number of products in this segment. Herceptin (Trastuzumab monoclonal antibody) is commonly prescribed breast cancer medicine. Roche developed Pertuzumab monoclonal antibody after the block buster success of Herceptin (Trastuzumab monoclonal antibody). It was approved in 2012 by the FDA for the treatment of or late stage metastatic HER2-positive breast cancer patients. Moreover, compounds such as Protein bound paclitaxel, tamoxifen, vinblastine, raloxifene, docetaxel and many more generic as well as branded drugs have shown positive results in reducing cancer progression and increasing life expectancy. Recently, branded drug such as Bevacizumab has seen preference among oncologists even though the drug has been advised to be removed from breast cancer indication. The market for metastatic breast cancer for now is highly fragmented between numerous drugs, radiation therapy and alternative therapies such as vitamin therapy, acupuncture, macrobiotic diets, homeopathy and herbal medication. Nano therapy via nano probe technology and various other areas of alternate treatment are under trials to check for their effectiveness in decreasing disease progression and arresting the cancerous cell growth by target specific tumor cell suppression. Historically, Herceptin has ruled the market in US and across the globe but due to its US patent expiration in 2019 its biosimilars might gain the same success stories. The driving forces behind the populariy of this drug are the increasing awareness of breast cancer by the means of several programs and screening aids. Another aspect is the emergence of targeted and combinational therapies. Drugs for the HER 2+ receptors such as Herceptin and Kadcyla can be administered as monotherapy or in the combination for the better survival rates. There are three specific medications that will be pushing this growth forward in breast cancer drug sales. These include; Novartis' Afinitor, Roche/Genentech's Perjeta, and trastuzumab-DM1. Afinitor has gained regulatory approval in Europe and the United States to market medication that treats hormone-receptor positive breast cancer, which is expected to raise this company's peak-year sales past US$ 1 Billion. US Breast Cancer Drug Market Outlook 2022 Report Highlights: - US Breast Cancer Tendencies - US Breast Cancer Drug Market Outline - US Breast Cancer Drug Market Dynamics - Breast Cancer Risk Undercurrents - US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis - US Breast Cancer Marketed Drugs Clinical Insight: 18 Drugs Key Topics Covered: 1. US Cancer Prevalence Rate 2. US Breast Cancer Tendencies 3. Breast Cancer Risk Undercurrents 4. US Breast Cancer Drug Market Outline 5. US Breast Cancer Drug Market Dynamics 6. US Breast Cancer Drug Market Future Aspects 7. Eribulin (Halaven) 8. Trastuzumab Emtansine (Kadcyla) 9. Palbociclib (Ibrance) 10. Pertuzumab (Omnitarg & Perjeta) 11. Gadobutrol (Gadavist, Gadovist & Gadovist 1.0) 12. Lapatinib (Tykerb) 13. Tamoxifen Oral Liquid (Soltamox) 14. Fulvestrant (Faslodex) 15. Anastrozole (Arimidex) 16. Ixabepilone (Ixempra) 17. Toremifene (Fareston) 18. Letrozole (Femara) 19. Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene)) 20. Exemestane (Aromasin) 21. Vitamin B12 Fluorescent-Analogues (CobalaFluor Green & CobalaFluor Red) 22. Trastuzumab Companion Diagnostic (HER2 CISH pharmDx) 23. Fluoxymesterone 24. Competitive Landscape
For more information about this report visit http://www.researchandmarkets.com/research/gk98ww/us_breast_cancer Related Topics: Women's Health, Breast Cancer Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005972/en/ |
